StockData

Orchestra BioMed vs Pulsenmore

OBIO and PLSM side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

obioOrchestra BioMed$7.25+64.0% in 1 yearplsmPulsenmore$1.38

How OBIO and PLSM compare

Orchestra BioMed grew revenue faster over the last twelve months (1007% versus 314% for Pulsenmore).

Orchestra BioMed scores higher on the StockData Score (9 against 3 for Pulsenmore), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricOBIOPLSM
Size and price
Market cap$436M–
Share price$7.25$1.38
Change, 1 year64.0%–
Change, 5 years−26.5%–
Beta (5Y)0.84–
Employees8663
StockData Score
Total score9 (better)3
Valuation score00
Growth score3 (better)2
Performance score1 (better)0
Health score5 (better)1
Dividend score00
Valuation
P/S14.0×–
FCF yield−14.7%–
Growth
Revenue growth (TTM)1007% (better)314%
EPS growth (TTM)–−57.3%
Profitability
Gross margin99.6% (better)84.2%
Operating margin−195%–
Net margin−183%–
FCF margin−206%−82.5% (better)
Financial health
Current ratio7.25 (better)1.84
Altman Z-score−3.18–
Piotroski F-score6–
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions46.1%5.5%
Held by insiders56.6%31.8%
Insider net buying, 12 months$6.1M (better)$15.7K
Superinvestors holding–1
Short interest, % of float10.5%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.